» Articles » PMID: 38202130

An Update on the Genetics of IgA Nephropathy

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jan 11
PMID 38202130
Authors
Affiliations
Soon will be listed here.
Abstract

Immunoglobulin A (IgA) nephropathy (IgAN), the most common form of glomerulonephritis, is one of the leading causes of end-stage kidney disease (ESKD). It is widely believed that genetic factors play a significant role in the development of IgAN. Previous studies of IgAN have provided important insights to unravel the genetic architecture of IgAN and its potential pathogenic mechanisms. The genome-wide association studies (GWASs) together have identified over 30 risk loci for IgAN, which emphasizes the importance of IgA production and regulation in the pathogenesis of IgAN. Follow-up fine-mapping studies help to elucidate the candidate causal variant and the potential pathogenic molecular pathway and provide new potential therapeutic targets. With the rapid development of next-generation sequencing technologies, linkage studies based on whole-genome sequencing (WGS)/whole-exome sequencing (WES) also identify rare variants associated with IgAN, accounting for some of the missing heritability. The complexity of pathogenesis and phenotypic variability may be better understood by integrating genetics, epigenetics, and environment. We have compiled a review summarizing the latest advancements in genetic studies on IgAN. We similarly summarized relevant studies examining the involvement of epigenetics in the pathogenesis of IgAN. Future directions and challenges in this field are also proposed.

Citing Articles

Single-Cell RNA-Sequencing Analysis Provides Insights into IgA Nephropathy.

Xia M, Li Y, Liu Y, Dong Z, Liu H Biomolecules. 2025; 15(2).

PMID: 40001494 PMC: 11853383. DOI: 10.3390/biom15020191.


What is new in the pathogenesis and treatment of IgA glomerulonephritis.

Salvadori M, Rosso G World J Nephrol. 2024; 13(4):98709.

PMID: 39723359 PMC: 11572654. DOI: 10.5527/wjn.v13.i4.98709.


Towards Risk Stratification in Clinical Care for IgA Nephropathy: Genetic Risk Scores: Comments on the Study "Clinical Application of Polygenic Risk Score in IgA Nephropathy".

Berthier C, Ju W Phenomics. 2024; 4(5):527-530.

PMID: 39723228 PMC: 11666848. DOI: 10.1007/s43657-024-00184-8.


Contemporary review of IgA nephropathy.

Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.

PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.

References
1.
Julian B, Quiggins P, Thompson J, Woodford S, Gleason K, Wyatt R . Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med. 1985; 312(4):202-8. DOI: 10.1056/NEJM198501243120403. View

2.
Gharavi A, Kiryluk K, Choi M, Li Y, Hou P, Xie J . Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011; 43(4):321-7. PMC: 3412515. DOI: 10.1038/ng.787. View

3.
Keramati A, Chen M, Rodriguez B, Yanek L, Bhan A, Gaynor B . Genome sequencing unveils a regulatory landscape of platelet reactivity. Nat Commun. 2021; 12(1):3626. PMC: 8206369. DOI: 10.1038/s41467-021-23470-9. View

4.
Ichii O, Otsuka S, Sasaki N, Namiki Y, Hashimoto Y, Kon Y . Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int. 2011; 81(3):280-92. DOI: 10.1038/ki.2011.345. View

5.
Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P . GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017; 13(2):e1006609. PMC: 5328405. DOI: 10.1371/journal.pgen.1006609. View